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INTRODUCTION
The normal menstrual cycle can be divided into two phases: follicular and luteal, which are 
separated by ovulation and bookended by the first day of menstrual bleeding. The follicular 
phase is dominated by the development of the preovulatory follicle, resulting in estrogen-
stimulated endometrial proliferation, whereas the corpus luteum (CL) of its namesake luteal 
phase produces progesterone, which inhibits endometrial proliferation and determines 
endometrial receptivity. Without both phases working in series, natural reproduction is not 
possible. This article focuses on the normal physiology of the luteal phase, investigates the 
controversy surrounding luteal phase defect, and describes the role of luteal phase support in 
assisted reproductive technology (ART).
LUTEAL PHASE PHYSIOLOGY
In the natural menstrual cycle, the follicular phase culminates with the maturation of the 
dominant follicle. Increasing estradiol, secreted from the granulosa cells inside the dominant 
follicle, triggers a surge of luteinizing hormone (LH) from the anterior pituitary. The LH 
surge propagates a series of events, beyond the scope of this article, that result in the 
breakdown of the connections of granulosa cells comprising the cumulus oophorous, reentry 
of the oocyte into the diplotene stage of prophase I of meiosis, and eventual rupture of the 
follicle and extrusion of the oocyte into the pelvis. While the oocyte is captured by the 
fimbria and possibly fertilized in the fallopian tubes, the postovulatory, deflated, and eggless 
follicle can easily be forgotten. However, the remaining follicular cells play an essential role 
in facilitating reproduction and maintaining normal menstrual cyclicity by forming the CL.
Before ovulation, the granulosa cells of the dominant follicle begin their transformation into 
the CL by enlarging and becoming vacuolated.1 The vacuoles take up the pigment lutein 
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(from the Latin luteus, meaning “yellow”) giving developing CL its characteristic yellow 
color. Before ovulation the granulosa cells are separated from the circulation by the basal 
lamina, necessitating nutrients and communications travel through gap junctions. With 
luteinization, the basal lamina regresses and the theca cells migrate into the forming CL. In 
addition, there is prompt neovascularization of the developing CL,2 mainly under the control 
of vascular endothelial growth factor and fibroblast growth factor, which are upregulated in 
the luteinized granulosa cells.3 The result of the impressive neovascularization is one of the 
highest blood flows per unit mass in the body,1 a fact clinically apparent to a gynecologist 
managing a hemorrhagic CL.
Although the CL secretes many different hormones, the sex steroid, progesterone, is of 
primary importance because it is necessary and sufficient to transform the endometrium to a 
state receptive to blastocyst implantation and to maintain early pregnancy.1 The production 
of progesterone by the luteal cells depends on the availability of its circulating cholesterol 
substrate and is facilitated by a low-level LH stimulation.4 To accomplish steroidogenesis, 
the luteal cells develop into 2 morphologic appearances, small and large cells, with distinct 
functions.5 The small cells, likely derived from the theca cells,6 contain LH and human 
chorionic gonadotropin (HCG) receptors.7 The LH receptor regulates low-density 
lipoprotein cholesterol receptor binding and internalization of the cholesterol.1 The large 
luteal cells are thought to arise from the granulosa cells.6 These cells have a greater 
steroidogenic capacity but lack the LH and HCG receptors needed to stimulate growth and 
provide cholesterol substrate.8 The small and large cells are linked by gap junctions 
facilitating rapid transport of signals between cells, providing a mechanism by which the 
large luteal cells, devoid of LH receptors, respond to LH stimulation and provide the 
primary source of progesterone.
Multiple experimental designs and clinical experience in patients undergoing ART treatment 
illustrate the importance of tropic LH secretion to progesterone production from the CL. In 
one classic experiment, rhesus monkeys with an obliterated median basal hypothalamus, 
and, therefore, absent gonadotropin-releasing hormone (GnRH) secretion, were given 
exogenous GnRH pulses of a uniform amplitude and frequency via a mechanical pump. 
When the GnRH pump was active during the luteal phase, LH and progesterone were 
secreted. Within hours of discontinuing GnRH pulses, LH and progesterone levels were 
undetectable.9 In women, lacking GnRH due to hypophysectomy, progesterone from the CL 
can be maintained with LH infusion.10 In women undergoing in vitro fertilization (IVF) with 
pituitary downregulation (lacking significant LH production), early ovarian progesterone 
production can be stimulated with supplementation of HCG, an LH analog. Further, the 
profound and rapid variation in progesterone levels throughout the luteal phase closely 
mimics LH pulsatility in the human11 and rhesus macaque.12
The individual CL seems to have a programmed lifespan independent of LH secretion. The 
normal lifespan of the CL is 11 to 17 days (mean 14.2 days) from the time of ovulation to 
the onset of menses.13 If not rescued by HCG production from a newly implanted 
pregnancy, the CL will regress into an avascular scar known as a corpus albicans, via a 
process termed luteolysis.14 Studies in rhesus monkeys have illustrated LH stimulation can 
be removed for up to 3 days without luteolysis. When it is reinstituted, progesterone 
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production returns, which suggests luteolysis is not an LH-dependent process.15 The process 
determining luteal phase length and degradation of the CL is still incompletely understood.
The CL can be rescued from luteolysis and continue progesterone production by rapidly 
rising HCG produced by the trophoblast of early pregnancy. Blastocysts grown in culture 
have been shown to produce HCG 7 to 8 days after fertilization.16 Although an early 
pregnancy is essential to the survival of the CL, a functioning CL is also essential to early 
pregnancy survival. The latter is evident in a classic series of studies by Csapo and 
colleagues17 who performed luteectomy in pregnant subjects. Luteectomy uniformly 
resulted in abortion if performed before 7 weeks gestation. If luteectomy was performed 
between 7 to 9 weeks, abortion was sometimes seen. Luteectomy after 9 weeks resulted 
uniformly in pregnancy survival. Additionally, pregnancy could be salvaged by 
progesterone supplementation after luteectomy. These findings dramatically illustrate the 
transition from the embryo’s dependence on the CL to the placental trophoblast for support 
and emphasize the absolute requirement for progesterone.18
The studies described above, as well as many others, highlight the essential role of luteal 
progesterone in pregnancy establishment and maintenance. Given this essential role, it is 
undeniable that there must be a progesterone threshold below which pregnancy 
establishment and/or maintenance is impaired or prevented. Thus, it is critical for the 
clinician to understand and recognize an abnormal luteal phase and understand the available 
therapies in both ART and non-ART cycles.
LUTEAL PHASE DEFICIENCY
Luteal phase deficiency (LPD) is a condition of insufficient progesterone exposure to 
maintain a normal secretory endometrium and allow for normal embryo implantation and 
growth.19 The condition was first described as a possible cause of infertility by Georgiana 
Seegar Jones20 in 1949. This early, elegant study investigated the luteal phase of 206 
ovulatory women with primary or secondary infertility. Some of these women were found to 
have a blunted rise in basal body temperature, decreased 48-hour urinary pregnanediol 
excretion, and/or endometrial biopsies with inadequate secretory changes, and labeled with 
LPD. Despite this early description and 65 further years of research, the understanding of 
LPD is still incomplete and controversy continues to surround its pathogenesis and 
diagnosis.21
LPD is sometimes clinically manifest by a shortened luteal phase lasting less than 9 days, 
from the day of ovulation to menstrual bleeding.20,22,23 LPD is also suspected when spotting 
begins many days before mensuration without a structural or infectious cause. LPD has been 
implicated as a cause of irregular menstrual bleeding,24 infertility,25,26 and recurrent 
pregnancy loss.23,27,28 However, despite the repeated association, a 2012 American Society 
for Reproductive Medicine (ASRM) committee opinion reminds readers that LPD has yet to 
be proven as a cause of infertility.19
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The Dilemma of Diagnosing Luteal Phase Deficiency
Confusion surrounding LPD is the result of inconsistent and unreliable diagnostic criteria. In 
the initial description, Jones20 provided clinical (shortened luteal phase), laboratory 
(decreased urinary pregnanediol), and histologic (endometrial biopsy) criteria for the 
diagnosis. Much of the research conducted since this initial description has used these 
methods singularly or in combination to identify affected individuals.
The normal luteal phase length from ovulation to menses ranges from 11 to 17 days with 
most luteal phases lasting 12 to 14 days. One proposed diagnostic criteria for LPD is a 
shortened luteal phase of less than 9 days.29 However, a short luteal phase can occur in up to 
5% of healthy fertile women with no significant increase in short luteal phase seen in the 
infertile population.13,30
Use of low luteal phase serum progesterone as a diagnostic tool for LPD is plagued by the 
pulsatile release of progesterone from the CL, echoing the pulsatile release of LH from the 
pituitary. Serum progesterone levels can fluctuate 8-fold in a 90-minute period during the 
midluteal phase and range from 2.3 to 40.1 pg/mL during a 24-hour period in the same 
healthy subject.11 Because this rapid fluctuation traverses almost the entire range of luteal 
values, there can be no standard for appropriate luteal phase progesterone in fertile women31 
and, therefore, a single value can neither diagnose nor exclude LPD in patients. It is 
suggested that the sensitivity and specificity of the test can be improved by evaluating 
pooled samples from three separate blood draws in the midluteal phase.31 However, the 
frequency and amplitude of progesterone pulses preclude sufficient precision. In the original 
description of LPD by Jones,20 daily luteal progesterone was offered as the most accurate, 
yet clinically impractical, diagnostic test. Other investigators have suggested a 24-hour or 
48-hour urinary pregnanediol glucuronide level to minimize progesterone fluctuations.32 
Remarkably, despite the clearly established barriers to its use, isolated serum progesterone 
concentrations are still used in the published literature to define biochemical LPD.23
The luteal phase biopsy, once considered the gold standard33 for LPD diagnosis, has also 
been shown to be too imprecise to be clinically useful for most patients. The goal of this test, 
previously considered by many clinicians to be a standard component of the fertility 
evaluation, was to detect histologic changes in the endometrium that were out of phase with 
the cycle in regard to days after ovulation.34 If the morphologic characteristics lagged more 
than 2 days behind the known luteal day, then LPD was presumed. In a study investigating 
histologic endometrial dating in healthy fertile volunteers, there was poor correlation 
between the actual cycle-day based on urinary detection of LH surge and histology report.35 
The study demonstrated a poorer precision in the timing of histologic features than had been 
described in previous studies using less rigorously timed biopsies. A large, multicenter, 
randomized trial designed to assess an association between and abnormal luteal phase 
biopsy and fertility failed to show usefulness. In this trial, 332 fertile women and 287 
infertile women underwent endometrial biopsy in the midluteal to late luteal phase. Contrary 
to expectations, out-of-phase biopsies were more common in the fertile women compared 
with their infertile counterparts (42.2% vs 32.7%, P<.05).36 Taken together, these studies 
provide strong evidence that histologic evaluation of the luteal phase biopsy to determine 
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luteal phase adequacy is imprecise and cannot distinguish between infertile subjects and 
fertile controls.
The ASRM committee opinion sums up these issues succinctly, “There is no reproducible, 
physiologically relevant, and clinically practical standard to diagnose LPD or distinguish 
fertile from infertile women.”19 The poor performance of the diagnostic tools used 
significantly complicates the interpretation of 65 years of research based on these tools. It is 
important to point out, however, that a test that is too imprecise to determine a disorder in an 
individual, may allow enrichment of groups with and without a disorder when applied to a 
larger population. However, the uncertainty is clearly driving research toward molecular 
biomarkers that may be a more specific tool for the evaluation of inadequate progesterone 
action.37
Pathophysiologic theories of luteal phase deficiency
Two mechanisms have been proposed as causes of clinical LPD. The first and likely more 
common cause relates to the impaired function of the CL resulting in insufficient 
progesterone and estradiol secretion.38 Impaired function can be the result of improper 
development of the dominant follicle destined to become the CL or aberrant stimulation of a 
normally developed follicle. Both mechanisms result in a CL with deficiencies in 
progesterone production. The second theory suggests an inability of the endometrium to 
mount a proper response to appropriate estradiol and progesterone exposure.39
Because the CL originates from the dominant follicles, it is logical to infer that abnormal 
development of the dominant follicle could result in an abnormal CL. Multiple studies have 
found a correlation between low follicular follicle-stimulating hormone (FSH) and LPD as 
defined by luteal phase progesterone secretion or luteal phase biopsy.40,41 However, other 
investigators have reported a normal FSH profile in the setting of luteal phase defect.42 
Abnormal LH pulsatility has also been implicated as a potential cause of LPD. Experiments 
by Soules and colleagues43 found some women with LPD have a fixed and increased LH 
pulse frequency throughout the early follicular phase compared with women with normal 
luteal function who have an accelerating LH pulse frequency approaching ovulation. It is 
suggested that an earlier increase in LH pulse frequency in the early follicular phase leads to 
decreased LH bioactivity in the luteal phase, decreasing progesterone secretion.44 The 
importance of pulsatile LH and FSH is further evidenced by patients receiving GnRH 
agonists or antagonists during ART cycles. These medications can cause suppression of 
pituitary LH secretion for 2 to 3 weeks after discontinuation, resulting in decreased CL 
progesterone production and necessitating progesterone supplementation for optimal 
outcomes.45
Another potential form of LPD is an abnormal endometrial response to adequate levels of 
progesterone exposure. Usadi and colleagues39 investigated normal, young research subjects 
who underwent modeled cycles, highly similar to endometrial preparation for donor oocyte 
recipience, except that progesterone levels were reduced to simulate LPD. These subjects 
underwent pituitary downregulation with a GnRH agonist and were supplemented with 
estradiol, to mimic the follicular phase, followed by estradiol and varying doses of 
progesterone to mimic the effects of the luteal phase on the endometrium. These 
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investigators found that unequivocally low levels of progesterone produced a completely 
normal appearing endometrium on histologic evaluation. The findings suggest that lower 
levels of progesterone might not be the sole culprit in LPD and there may be other molecular 
mechanisms affecting abnormal responses to progesterone and, therefore, abnormal 
endometrial development and receptivity.
Treatment of luteal phase deficiency
Due to the incomplete understanding of the pathophysiology and lack of an accurate method 
to diagnose LPD, empiric treatment of suspected LPD cannot be completely evidence-based. 
Clinical studies of treatment regiments are faced with a catch-22: how to evaluate treatment 
in a disease that cannot be accurately diagnosed. Most studies have used improvements in 
surrogate markers, such as endometrial biopsy and progesterone level, to show treatment 
effect. Unfortunately all attempts to link these surrogate outcomes to fertility outcomes have 
been unsuccessful.19 Although these limitations preclude effective study of treatment 
regiments, they do not designate treatment attempts as nonsensical. Instead, this is an area in 
which many treating physicians believe that the art of medicine plays a role and they 
continue to treat patients they suspect to be affected by a LPD. In this scenario, the risk of 
the treatment must be exceptionally small.
Before considering treatment of LPD, it is important to evaluate and treat underlying 
conditions, such as hypothyroidism and hyperprolactinemia, which can alter the 
hypothalamic-pituitary-ovary axis function, causing abnormalities in hormone production. If 
clinical suspicion over multiple cycles points to LPD as a cause of infertility or miscarriage, 
it is reasonable to consider empiric treatment to correct LPD. Two strategies, improving the 
follicular development and supplementing progesterone, have been used to correct suspected 
LPD and treat infertility or recurrent miscarriage.
Extrapolating from studies showing impaired luteal progesterone secretion with lower 
gonadotropins in the follicular phase, it is inferred that more robust or numerous mature 
follicles will improve luteal progesterone secretion from the CL, correcting LPD. Therefore, 
many clinicians treat suspected LPD by attempting to optimize follicular development and 
number using ovulation induction agents, including clomiphene citrate (CC), letrozole, or 
injectable gonadotropins. To the authors’ knowledge, only one small study has investigated 
the effect of clomiphene in subjects with LPD (diagnosed by out-of-phase endometrial 
biopsy).46 In this study, designed to determine if the number of mature follicles after 100 mg 
of CC on cycle days 5 to 9 had an effect on endometrial biopsy, 10 out of 18 subjects with 
previously out-of-phase biopsies had an in-phase biopsy after receiving 100 mg of CC. 
However, how many would have had the same without CC cannot be determined. In a small 
retrospective study of 23 women investigating the use of injectable gonadotropins in women 
with presumed LPD and recurrent pregnancy loss, a significantly lower miscarriage rate was 
seen in those using gonadotropins versus controls (15% vs 58%).47 To date, there are no 
published studies evaluating the effectiveness of ovulation induction with letrozole in 
women with LPD.
Progesterone supplementation is suggested as a treatment of LPD. Although frequently used, 
there is no published evidence that it improves pregnancy outcomes in natural cycles.19 
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Progesterone may be supplied as micronized progesterone or synthetic progestins. Given 
reports of teratogenicity associated with synthetic progestins48 (that have since been 
disproven49), natural micronized progesterone has been the treatment of choice. Micronized 
progesterone can be potentially supplied orally, sublingually, rectally, as an oil-based 
vaginal suppository, an aqueous vaginal cream, or intramuscularly (see later discussion).
A retrospective study comparing the CC treatment to progesterone vaginal suppositories in 
patient with presumed LPD based on endometrial biopsy showed a 100% pregnancy rate in 
those treated with progesterone and an 81% pregnancy rate in those treated with CC after 1 
year.50 These groups were compared with a historical population control with a pregnancy 
rate of 93%, suggesting effectiveness of treatment of LPD. A meta-analysis evaluated 3 
underpowered controlled trails that failed to show a positive effect of progesterone treatment 
of recurrent pregnancy loss in patients with LPD.51 When the studies were pooled, the odds 
ratio (OR) for ongoing pregnancy after treatment with progesterone was 3.09 (95% CI 1.28–
7.42), suggesting a beneficial effect of progesterone. Well-designed randomized trials are 
needed to definitively answer whether ovulation induction or luteal progesterone 
supplementation is beneficial for patients with LPD.
It is the authors’ clinic practice to consider treatment in patients with a clinical suggestion of 
LPD, including infertility or recurrent miscarriage in women with a short luteal phase or 
intermenstrual spotting without an identifiable cause. We typically treat with ovulation 
induction agents (50 mg CC or 2.5 mg letrozole on cycle day 5–9) and/or 200 mg 
micronized progesterone in oil suppositories beginning 3 to 4 days after LH surge. In 
patients with recurrent loss, the progesterone supplementation is often given after the first 
positive pregnancy test. We do not treat suspected LPD with injectable gonadotropins, given 
the high cost and unacceptable risk of twins or higher order multiples. We acknowledge 
these treatments are not based on strong evidence; however, they are based on clinical 
interpretation of underlying physiology and come with few risks.
LUTEAL PHASE SUPPORT DURING ASSISTED REPRODUCTION
Treatments that encompass ART include IVF, intracytoplasmic sperm injection (ICSI), and 
frozen embryo transfer (FET). These treatments frequently result in either the transfer of an 
embryo into a woman who has undergone controlled ovarian hyperstimulation with 
subsequent oocyte retrieval or a woman receiving an embryo in a nonovulatory cycle (FET 
or fresh embryo transfer of embryos from donor eggs into a recipient). In both situations, 
there is an effective LPD. In the patients who are receiving embryos in nonovulatory cycles, 
the need for progesterone supplementation is easy to understand given the absent CL. These 
are cycles in which the natural cyclicity is absent or suppressed, and the endometrial effects 
of the follicular phase are mimicked with estradiol supplementation to cause a proliferative 
endometrium. To prepare the endometrium for implantation of the embryo, the luteal phase 
is mimicked by exposing the endometrium to progesterone. Timing the transfer of an 
embryo to the appropriate duration of progesterone exposure allows for successful 
implantation. It is also clear that the luteal phase following controlled ovarian 
hyperstimulation and oocyte aspiration is dysfunctional, a fact that has been recognized 
since the infancy of IVF.52 However, the reason for this deficiency is still controversial.53 
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Multiple explanations for this phenomenon have been reported and subsequently disputed. It 
was initially assumed that the LPD after IVF resulted from destruction of granulosa cells 
destined to become the CL during oocyte aspiration. This theory was questioned after no 
changes in progesterone levels or luteal phase length were seen after aspiration of the single 
mature follicle in a natural, unstimulated cycle.54 The administration of HCG to mimic the 
LH surge in IVF has been implicated as a cause of LPD by inhibition endogenous LH 
secretion from the pituitary.55 However, normal luteal phase length and pregnancy rates are 
routinely seen in women receiving HCG triggers in natural cycles or while undergoing 
superovulation and intrauterine insemination. Other investigators have posited that the LPD 
is the result of GnRH agonist used to downregulate pituitary LH secretion, suppressing LH 
secretion well into the luteal phase.45 With the advent of GnRH antagonists, which clear 
quickly and do not cause long-term pituitary LH suppression, premature luteolysis and poor 
pregnancy rates were seen when used during IVF cycles without progesterone support,56 
illustrating prolonged GnRH agonist pituitary suppression cannot be the sole cause of LPD 
in women undergoing IVF. Currently, the most widely accepted theory of LPD after IVF 
states the supraphysiologic steroid hormones secreted by the multiple CL in the early luteal 
phase of an IVF cycle causes direct inhibition of LH secretion via negative feedback on the 
hypothalamic-pituitary axis.56–58
The optimization of ART success rates relies not only on the creation of high-quality 
embryos but also on the establishment of a receptive endometrium. During the past 35 years, 
since the first IVF pregnancy and subsequent first pregnancy from frozen embryos, 
significant research has been directed toward establishing the optimum supplementation of 
the luteal phase in both IVF and FET cycles, with a goal to maximize live births while 
minimizing patient discomfort and inconvenience.
Luteal Phase Support in In Vitro Fertilization
Multiple treatments options, including progesterone, HCG, and GnRH agonist, have been 
tested in luteal phase supplementation after IVF. A recent Cochrane systematic review has 
evaluated many of these options and will be referred to in the remainder of this article.53 In a 
recent survey of ART providers by Vaisbuch and colleagues,59 all of the 408 centers across 
82 countries used some form of progesterone for luteal phase support, with none of the 
surveyed centers using solely HCG, a historical treatment option. This is a change from a 
similar survey conducted 3 years earlier in which 5% of the IVF clinics were using HCG as 
the sole agent for luteal support.60 Although luteal HCG has a similar effectiveness to luteal 
progesterone in terms of pregnancy outcomes, the avoidance of luteal HCG is due to the 
increased risk of ovarian hyper-stimulation syndrome with this medication.53,61,62 Given the 
paucity of use, luteal support with HCG is not further considered in this article.
Progesterone supplementation is available in multiple preparations, including intramuscular, 
vaginal, oral, or in a newly developed subcutaneous preparation. In a 2014 survey of 
284,600 IVF cycles in 82 separate centers, 77% of the cycles were performed with vaginal 
progesterone only and an additional 17% used vaginal progesterone in combination with 
oral or intramuscular progesterone. Just 5% used only intramuscular progesterone and 0.5% 
used only oral progesterone.59 However, there were regional differences in the choice of 
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progesterone preparation with 57% of North American cycles choosing intramuscular 
progesterone. Subcutaneous progesterone is still in the trial phase.
Oral micronized progesterone was the luteal support progesterone of choice in the 1980s; 
however, it has since proven to be a poor treatment option. Although the most convenient 
form of progesterone, micronized progesterone, has poor and inconsistent bioavailability. 
After ingestion, it is absorbed by the intestines, undergoes a first-pass metabolism by the 
liver, and is excreted by the kidneys, resulting in a bioavailability that is only 10% of 
intramuscular preparations.63 Serum levels reach maximum in 2 to 4 hours and remain 
significantly elevated for only 6 to 7 hours,64 requiring more frequent dosing. In a 
randomized, controlled trial, users of oral micronized progesterone had a significantly 
decreased implantation rate compared with users of intramuscular progesterone (18.1 vs 
40.9%, P = .004).65 In a second trial, when compared against vaginal micronized 
progesterone, the oral route once again resulted in a lower implantation rate (10.7 vs 30.7%, 
P≤.01).66
Given the allure of an oral agent for luteal support, other oral agents have been studied to 
replace oral micronized progesterone. Dydrogestrone, is an oral progestin with improved 
bioavailability compared with oral micronized progesterone.67 In one randomized, 
controlled trial, pregnancy rates were higher in women undergoing IVF using oral 
dydrogesterone for luteal support versus vaginal micronized progesterone (41.0 vs 29.4%, 
P≤.01).68 A second trial comparing the same agents showed similar pregnancy rates.69 
Another randomized, controlled trial compared oral dydrogesterone to micronized 
progesterone vaginal gel (Crinone 8%) and found similar pregnancy rates (28.7 vs 28.6%).70 
Another synthetic progesterone, chlormadinone acetate, was compared with intramuscular 
progesterone with no changes in pregnancy rates or implantation rates.71 In the 2011 
Cochrane review, analysis favored the use of synthetic progesterone compared with 
micronized progesterone for clinical pregnancy (OR, micronized progesterone use: 0.79, 
95% CI 0.65–0.96).53
Intramuscular progesterone was first described as a form of luteal supplementation during 
IVF in 1985.72 The use of intramuscular progesterone is associated with injection site pain, 
skin irritation, inflammatory reactions, and rare abscess formation.73 Early randomized trials 
comparing intramuscular progesterone to vaginal progesterone showed superior pregnancy 
rates in the intramuscular group.73,74 However, since this time, multiple other randomized 
trials using newer progesterone preparations have been conducted and a 2009 meta-analysis 
showed no difference between the 2 groups in pregnancy rates and ongoing pregnancy 
rates.75 A 2011 Cochrane review showed no difference in pregnancy or live birth rate; 
however, it did find a difference favoring intramuscular progesterone in ongoing pregnancy 
rates.53 Intramuscular and vaginal administration of luteal progesterone are now considered 
by most investigators as equivalent in terms of IVF pregnancy outcomes.
Vaginal preparations of progesterone have become the mainstay of luteal supplementation 
during IVF because of their relative ease of use and equivalence to intramuscular 
progesterone. Vaginal progesterone is typically available as a tablet, suppository, or 8% gel. 
Vaginal progesterone benefits from a first-pass uterine effect in which endometrial tissue 
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concentrations are typically much greater than would be expected based on serum levels.76 
Pharmacy-compounded vaginal suppositories are typically discouraged in IVF cycles due to 
unreliable and variable progesterone levels.77 In a large, multicenter, randomized, controlled 
trial, progesterone tablets (Endometrin 100 mg twice a day or 3 times a day) were compared 
with 8% progesterone gel (Crinone 8% gel) with similar pregnancy and live birth rates 
between the 3 groups (live birth rate, Endometrin twice a day 35%, Endometrin 3 times a 
day 38%, Crinone gel 38%, normal saline).78 Vaginal progesterone is well tolerated by most 
patients although some dislike this medication because of higher cost than injectable forms, 
difficulty with administration, and/or vaginal discharge.
Recently, a water-soluble injectable progesterone complex (Prolutex) has been developed 
for subcutaneous administration.79 A pharmacokinetic study of this compound demonstrated 
sufficient serum progesterone levels to allow clinical use in ART.80 To date, 2 randomized 
noninferiority trials have been conducted. The first compared subcutaneous progesterone 
(Prolutex) to 8% progesterone gel (Crinone) as luteal phase supplementation during IVF 
with no difference in ongoing pregnancy rate (27.7 vs 30.5%, P = NS).81 A second 
randomized trial compared subcutaneous progesterone (Prolutex) to vaginal progesterone 
tablets (Endometrin) with no change in ongoing pregnancy rate (40.8 vs 43.3%).82 Common 
side effects related to the subcutaneous injection include injection site pain, bruising, 
inflammation, and edema.
There is currently no consensus on when to begin progesterone supplementation during an 
IVF cycle. The first dose of progesterone is typically administered between the between the 
day of retrieval to 2 days after retrieval with no obvious changes in pregnancy rates.83,84 
Insight into the timing of embryo transfer in relation to progesterone exposure can be 
gathered from an experiment by Prapas and colleagues.85 Vaginal or intramuscular 
progesterone exposure before transfer of fresh embryos from donor oocytes was varied from 
2 to 6 days and implantation and clinical pregnancy rates were highest in a narrow window 
of progesterone exposure (Fig. 1). Most surveyed clinics (80.1%) begin progesterone 
supplementation on the day of egg retrieval.59 In addition there is no consensus on the 
duration of progesterone use. A recent meta-analysis of 6 eligible studies and 1201 
randomized subjects concluded there may be no additional benefit of progesterone 
supplementation beyond the first positive HCG value, showing no difference in live birth 
(risk ratio [RR]: 0.95, CI 0.86–1.05), ongoing pregnancy (RR: 0.97, CI 0.90–1.05), or 
miscarriage (RR: 1.01, CI 0.74–1.38).86 Despite these data, most surveyed clinics (72%) 
continue progesterone until 8 weeks or more of pregnancy and only 15% discontinue 
progesterone after detection of beta HCG.59
Adjuvants to progesterone supplementation to increase IVF pregnancy rates have been 
widely discussed in the literature. The CL is not only a source of progesterone but also 
produces estradiol, along with many nonsteroidal hormones. Therefore, it has been 
suggested luteal support should include estradiol supplementation.87 A 2008 meta-analysis 
identified 4 randomized studies evaluating estradiol supplementation in the luteal phase and 
found no difference between clinical pregnancy (587 subjects, RR: 0.94, CI 0.78–1.13) and 
live birth (527 subjects, RR: 0.96, CI 0.77–1.21).88 In the 2011 Cochrane review, 
progesterone plus estradiol did not perform any better than progesterone in terms of 
Mesen and Young Page 10













biochemical pregnancy, clinical pregnancy, or live birth. However, when a subgroup 
analysis of clinical pregnancy was performed, progesterone alone performed worse then 
progesterone plus transdermal estradiol (OR: 0.50, CI 0.31–0.82), suggesting route of 
estradiol administration may play a role.53
Another suggested adjuvant to progesterone supplementation is a single dose of GnRH 
agonist 5 to 6 days after oocyte retrieval. It is hypothesized the GnRH agonist may support 
the CL by stimulating LH secretion for the pituitary but also may have effects on the 
endometrial GnRH receptors or direct effects on the embryo.89 A 2010 meta-analysis90 
evaluated 5 randomized, controlled trials investigating luteal phase GnRH agonist91–95 in 
both long and GnRH-antagonist protocols. When data were pooled, there was an increased 
pregnancy rate in cycles in which a single dose of luteal GnRH agonist was given 5 to 6 
days after oocyte retrieval (42.4 vs 35.7%, OR: 1.33, 95% CI 1.08–1.64). A subgroup 
analysis was performed and pregnancy rate was significantly higher with luteal GnRH 
agonist used in a GnRH antagonist stimulation compared with the long protocol. Similarly, 
the recent Cochrane review showed increased pregnancy, ongoing-pregnancy, and live birth 
rates in subjects receiving luteal GnRH agonists.53 Despite promising early evidence, 
additional study is needed given the lack of clear biologic mechanism before wide 
acceptance of this practice.
Luteal Phase Progesterone During Frozen Embryo Transfer and Donor or Recipient Cycles
Data from IVF cycles should not be extrapolated to FET or donor or recipient cycles 
because, unlike IVF cycles, there is no formed CL, thus no endogenous source of 
progesterone. In these cycles, exogenous estradiol is typically used to proliferate the 
endometrium, then exogenous progesterone is added to induce secretory changes in 
preparation for implantation. Intramuscular progesterone is typically used for this purpose in 
the United States, whereas in Europe vaginal progesterone is preferred.96 Unfortunately, 
there are a paucity of data on this topic and, therefore, treatment decisions are based on 
limited information. Two small, prospective, randomized trials from the same group showed 
no difference in ongoing pregnancy rate when comparing intramuscular progesterone to 
vaginal progesterone in recipients of donor oocytes.97,98 In addition, a retrospective study of 
donor oocyte recipients99 and another retrospective study of subjects receiving donor and 
autologous frozen blastocysts100 showed no difference in implantation, clinical pregnancy, 
or live birth rates. However, 2 other retrospective studies of women undergoing FET 
illustrated a deceased live birth rate in subjects receiving vaginal progesterone (24.4 vs 
39.1%)101 and (22.8 vs 34.5%).102 The timing of progesterone exposure in FET and donor 
cycles has not been fully studied; however, a review of luteal progesterone during FET 
cycles was performed by Nawroth and Ludwig103 and concluded cleavage-stage embryos 
should not be transferred before 3 to 4 days of progesterone treatment. In the clinical studies 
mentioned above,97–102 cleavage-stage embryos were transferred on the fourth day of 
progesterone exposure and blastocyst were transferred on the sixth day of progesterone 
exposure.
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Progesterone production from the CL is critical for natural reproduction and progesterone 
supplementation seems to be an important aspect of any ART treatment. LPD in natural 
cycles is a plausible cause of infertility and pregnancy loss, although there is no adequate 
diagnostic test. Future research should concentrate on establishing thresholds of 
progesterone dose and timing for fertile and infertile women, as well as on a precise and 
accurate diagnostic test.
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• Luteal phase deficiency is a disease without a reliable diagnostic test, impairing 
clinical research and patient care.
• Exogenous progesterone is the primary agent for luteal support during assisted 
reproductive technology treatment; however, the best delivery method, protocol, 
and formulation are not yet known.
• Vaginal or intramuscular progesterone seem to be equivalent in terms of 
pregnancy outcomes after in vitro fertilization.
• The best route of progesterone supplementation after frozen embryo transfer is 
not yet established.
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Effect of days of progesterone exposure on implantation and pregnancy rates after cleavage-
stage embryo transfer from donor oocytes. (Data from Prapas Y, Prapas N, Jones EE, et al. 
The window for embryo transfer in oocyte donation cycles depends on the duration of 
progesterone therapy. Hum Reprod 1998;13(3):720–3.)
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